Cantargia receives patent approval from the USPTO for IL1RAP in acute lymphoblastic leukemia

The United States Patent and Trademark Office (“USPTO”) has formally granted
Cantargia AB’s (“Cantargia”) patent application for use of IL1RAP as target
molecule for antibody therapy of acute lymphoblastic leukemia (“ALL”). The
approval follows the Notice of Allowance that was issued and communicated in
June 2016.
The approved patent with number US 9,458,237 will be published October 4, 2016
and provides protection until 2030 and covers Cantargia’s method of using IL1RAP
as target molecule for treatment of ALL.

“The US is one of the largest markets for Cantargia, so this is of course good
news. Having received formal approval from the US, this patent has now been
approved in the US, Europe, Australia, Mexico, Japan and South Africa. This
gives us very good protection in respect of ALL in important markets around the
world”, says Göran Forsberg, CEO of Cantargia.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This constitutes information that Cantargia is required to publish under the
EU’s Market Abuse Regulation. The information was submitted for publication
through the above contact person on 16 September 2016, at 8:30 am.